Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 248

1.

Incretin-based therapies, glucometabolic health and endovascular inflammation.

Rizzo M, Nikolic D, Banach M, Patti AM, Montalto G, Rizvi AA.

Curr Pharm Des. 2014;20(31):4953-60. Review.

PMID:
24320037
2.
3.

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Neumiller JJ.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078. Review.

PMID:
19801361
4.

Incretins: their physiology and application in the treatment of diabetes mellitus.

Tasyurek HM, Altunbas HA, Balci MK, Sanlioglu S.

Diabetes Metab Res Rev. 2014 Jul;30(5):354-71. doi: 10.1002/dmrr.2501. Review.

PMID:
24989141
5.

Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.

Campbell RK.

Clin Ther. 2011 May;33(5):511-27. doi: 10.1016/j.clinthera.2011.04.015. Review.

PMID:
21665040
6.

CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR?

Mora PF, Johnson EL.

Endocr Pract. 2017 Jan;23(1):89-99. doi: 10.4158/EP161481.RA. Epub 2016 Nov 7. Review.

PMID:
27819769
7.

Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.

Freeman JS.

Cleve Clin J Med. 2009 Dec;76 Suppl 5:S12-9. doi: 10.3949/ccjm.76.s5.03. Review.

8.

The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.

Morales J.

Postgrad Med. 2011 Nov;123(6):189-201. doi: 10.3810/pgm.2011.11.2508. Erratum in: Postgrad Med. 2012 Jan;124(1):177-8.

PMID:
22104467
9.

Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.

Vergès B, Bonnard C, Renard E.

Diabetes Metab. 2011 Dec;37(6):477-88. doi: 10.1016/j.diabet.2011.07.001. Epub 2011 Aug 25. Review.

PMID:
21871831
10.

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Jellinger PS.

Postgrad Med. 2011 Jan;123(1):53-65. doi: 10.3810/pgm.2011.01.2245. Review.

PMID:
21293084
11.

Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.

van Genugten RE, Möller-Goede DL, van Raalte DH, Diamant M.

Diabetes Obes Metab. 2013 Jul;15(7):593-606. doi: 10.1111/dom.12050. Epub 2013 Jan 21. Review.

PMID:
23216746
12.

Incretin-based therapies: therapeutic rationale and pharmacological promise for type 2 diabetes.

Wick A, Newlin K.

J Am Acad Nurse Pract. 2009 Nov;21 Suppl 1:623-30. Review.

PMID:
19900193
13.
14.

Differentiating incretin-based therapies for population-based health care.

Calabrese D.

Am J Manag Care. 2011 Mar;17(2 Suppl):S52-8.

15.

Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.

Boland CL, Degeeter M, Nuzum DS, Tzefos M.

Ann Pharmacother. 2013 Apr;47(4):490-505. doi: 10.1345/aph.1R444. Epub 2013 Apr 2. Review.

PMID:
23548652
16.

Incretin-based therapy of type 2 diabetes mellitus.

Knop FK, Vilsbøll T, Holst JJ.

Curr Protein Pept Sci. 2009 Feb;10(1):46-55. Review.

PMID:
19275672
17.

Incretin-based therapies and cardiovascular risk.

Mannucci E, Dicembrini I.

Curr Med Res Opin. 2012 May;28(5):715-21. doi: 10.1185/03007995.2012.678940. Epub 2012 Apr 13. Review.

PMID:
22439700
18.
19.

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.

Russell S.

Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22. Review.

PMID:
23263796

Supplemental Content

Support Center